A5082713013- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Renal Diseases and Glomerulopathies
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Reproductive System and Pregnancy
- Pregnancy and Medication Impact
- Platelet Disorders and Treatments
- Cytokine Signaling Pathways and Interactions
- Peripheral Neuropathies and Disorders
- Liver Diseases and Immunity
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Drug-Induced Ocular Toxicity
- Diabetes and associated disorders
- Pregnancy and preeclampsia studies
- Blood disorders and treatments
- Protein Tyrosine Phosphatases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Complement system in diseases
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
Johns Hopkins Medicine
2016-2025
Johns Hopkins University
2016-2025
Johns Hopkins Hospital
2006-2024
University of Michigan
2005-2024
Stanford University
2024
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research
2024
Genomics Medicine (Ireland)
2024
Greater Baltimore Medical Center
2023
Triangle
2023
Indianapolis Zoo
2023
The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, incorporate new knowledge regarding immunology SLE.The were derived from a set 702 expert-rated patient scenarios. Recursive partitioning was used derive an initial rule that simplified refined based on SLICC physician...
To assess the efficacy/safety of B lymphocyte stimulator inhibitor belimumab plus standard therapy compared with placebo in active systemic lupus erythematosus (SLE).In a phase III, multicenter, randomized, placebo-controlled trial, 819 antinuclear antibody-positive or anti-double-stranded DNA-positive SLE patients scores ≥6 on Safety Estrogens Lupus Erythematosus National Assessment (SELENA) version Disease Activity Index (SLEDAI) were randomized 1:1:1 ratio to receive 1 mg/kg belimumab, 10...
Abstract Objective To examine mortality rates in the largest systemic lupus erythematosus (SLE) cohort ever assembled. Methods Our sample was a multisite international SLE (23 centers, 9,547 patients). Deaths were ascertained by vital statistics registry linkage. Standardized ratio (SMR; of deaths observed to expected) estimates calculated for all and cause. The effects sex, age, duration, race, calendar‐year periods determined. Results overall SMR 2.4 (95% confidence interval 2.3–2.5)....
Oral contraceptives are rarely prescribed for women with systemic lupus erythematosus, because of concern about potential negative side effects. In this double-blind, randomized, noninferiority trial, we prospectively evaluated the effect oral on activity in premenopausal erythematosus.
Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger are desirable.We conducted a 24-week randomized, open-label, noninferiority trial comparing oral (initial dose, 1000 mg per day, increased to 3000 day) with monthly intravenous cyclophosphamide (0.5 g square meter of body-surface area, 1.0 meter) as induction therapy active nephritis. A change the alternative regimen was allowed at 12 weeks...
Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease in which the risk of influenced by complex genetic and environmental contributions. Alleles HLA-DRB1, IRF5, STAT4 are established susceptibility genes; there strong evidence for existence additional loci.
To test the reliability of Systemic Lupus International Collaborating Clinics/American College Rheumatology (SLICC/ACR) Damage Index and Erythematosus Disease Activity (SLEDAI) in assessment patients with SLE.Ten SLE, representing a spectrum damage activity, were included. Each patient was examined by 6 10 physicians from 5 countries, lupus clinics. The SLICC/ACR used to assess accumulated damage, SLEDAI disease activity. order randomized according Youden square design.The detected...
Background: There is concern that exogenous female hormones may worsen disease activity in women with systemic lupus erythematosus (SLE). Objective: To evaluate the effect of hormone replacement therapy (HRT) on postmenopausal SLE. Design: Randomized, double-blind, placebo-controlled noninferiority trial conducted from March 1996 to June 2002. Setting: 16 university-affiliated rheumatology clinics or practices 11 U.S. states. Patients: 351 menopausal patients (mean age, 50 years) inactive...
Abstract Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard care therapy (SOC) patients active systemic lupus erythematosus (SLE). Methods Patients a Safety Estrogens Lupus Erythematosus: National Assessment (SELENA) version Systemic Erythematosus Disease Activity Index (SLEDAI) score ≥4 (n = 449) were randomly assigned to (1, 4, or 10 mg/kg) placebo 52‐week study. Coprimary end points percent change SELENA–SLEDAI at week...
Rheumatic diseases in women of childbearing years may necessitate drug treatment during a pregnancy, to control maternal disease activity and ensure successful pregnancy outcome. This survey is based on consensus workshop international experts discussing effects anti-inflammatory, immunosuppressive biological drugs lactation. In addition, these male female fertility possible long-term infants exposed antenatally are discussed where data were available. Recommendations for lactation given.
Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort. Methods. Patients the Systemic Lupus International Collaborating Clinics cohort (≤15 months of diagnosis) were assessed annually for estimated glomerular filtration rate (eGFR), proteinuria and end-stage renal disease (ESRD). Health-related quality life was measured by Short Form (36 questions) health survey questionnaire (SF-36) subscales, mental physical component summary scores. Results....
Abstract Objective Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy. The purpose of this study was examine and pregnancy outcomes women with SLE treated or not HCQ Methods This a prospective pregnancies who were evaluated between 1987 2002. divided into 3 groups: no exposure (163 pregnancies), continuous use (56 cessation treatment either the months prior first trimester (38 pregnancies). outcomes, fetal compared among...
The restriction of phosphatidylserine (PtdSer) to the inner surface plasma membrane bilayer is lost early during apoptosis. Since PtdSer a potent procoagulant, and since there an increased incidence coagulation events in patients with systemic lupus erythematosus (SLE) who have anti-phospholipid antibodies, we addressed whether apoptotic cells are procoagulant antibodies influence this. Apoptotic HeLa cells, human endothelial murine pre-B-cell line were markedly modified Russell viper venom...
<h3>Background and aims</h3> We studied damage accrual factors determining development progression of in an international cohort systemic lupus erythematosus (SLE) patients. <h3>Methods</h3> The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months developing four or more 1997 American College Rheumatology (ACR) criteria for SLE; the SLICC/ACR index (SDI) was measured annually. assessed relative rates transition using maximum...
Objective To evaluate the association between corticosteroid use and organ damage in patients with systemic lupus erythematosus (SLE). Methods The occurrence date of damage, as measured by Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage Index, were determined for 539 enrolled Hopkins Cohort Study. risk associated cumulative prednisone dose, high-dose (≥60 mg/day ≥2 months), pulse methylprednisolone (1,000 mg intravenously 1–3 days) was estimated using...
Background: Because systemic lupus erythematosus (SLE) affects women of reproductive age, pregnancy is a major concern. Objective: To identify predictors adverse outcomes (APOs) in patients with inactive or stable active SLE. Design: Prospective cohort. Setting: Multicenter. Patients: 385 (49% non-Hispanic white; 31% prior nephritis) SLE the PROMISSE (Predictors Pregnancy Outcome: Biomarkers Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study. Exclusion criteria were...
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by production of autoantibodies against intracellular antigens including DNA, ribosomal P, Ro (SS-A), La (SS-B), and the spliceosome. Etiology suspected to involve genetic environmental factors. Evidence involvement includes: associations with HLA-DR3, HLA-DR2, Fcgamma receptors (FcgammaR) IIA IIIA, hereditary complement component deficiencies, as well familial aggregation, monozygotic twin concordance >20%, lambdas >...